Sifalimumab, a Human Anti–Interferon‐α Monoclonal Antibody, in Systemic Lupus Erythematosus: A Phase I Randomized, Controlled, Dose‐Escalation Study

Petri, Michelle; J. Wallace, Daniel; Spindler, Alberto; Chindalore, Vishala; Kalunian, Kenneth; Mysler, Eduardo; Michael Neuwelt, C.; J. Robbie, Gabriel; I. White, Wendy; W. Higgs, Brandon; Yao, Yihong; Wang, Liangwei; Ethgen, D; Greth, Warren

doi:10.1002/art.37824

Public

Sifalimumab, a Human Anti–Interferon‐α Monoclonal Antibody, in Systemic Lupus Erythematosus: A Phase I Randomized, Controlled, Dose‐Escalation Study

Published in Arthritis & Rheumatism • Feb 11, 2013

Authors:

Michelle Petri

Daniel J. Wallace

Alberto Spindler

Abstract

OBJECTIVE: To evaluate the safety and tolerability of multiple intravenous (IV) doses of sifalimumab in adults with moderate-to-severe systemic lupus erythematosus (SLE). METHODS: In this multicenter, double-blind, placebo-controlled, sequential dose-escalation study, patients were randomized 3:1 to...

Subject

Medicine

Tolerability

Placebo

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!